AstraZeneca’s diabetes drug Bydureon (exenatide) has failed to slow the progression of Parkinson’s disease motor symptoms in a Phase III trial. The University College London (UCL) in the UK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback